HomeCompareWLTW vs ABBV

WLTW vs ABBV: Dividend Comparison 2026

WLTW yields 18.65% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WLTW wins by $8.80M in total portfolio value
10 years
WLTW
WLTW
● Live price
18.65%
Share price
$231.56
Annual div
$43.19
5Y div CAGR
37.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.90M
Annual income
$6,170,593.00
Full WLTW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WLTW vs ABBV

📍 WLTW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWLTWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WLTW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WLTW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WLTW
Annual income on $10K today (after 15% tax)
$1,585.25/yr
After 10yr DRIP, annual income (after tax)
$5,245,004.05/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, WLTW beats the other by $5,223,948.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WLTW + ABBV for your $10,000?

WLTW: 50%ABBV: 50%
100% ABBV50/50100% WLTW
Portfolio after 10yr
$4.50M
Annual income
$3,097,682.38/yr
Blended yield
68.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WLTW
Analyst Ratings
12
Buy
12
Hold
2
Sell
Consensus: Buy
Price Target
$253.00
+9.3% upside vs current
Range: $225.00 — $300.00
Altman Z
1.2
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WLTW buys
0
ABBV buys
0
No recent congressional trades found for WLTW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWLTWABBV
Forward yield18.65%3.06%
Annual dividend / share$43.19$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37.3%40.6%
Portfolio after 10y$8.90M$102.3K
Annual income after 10y$6,170,593.00$24,771.77
Total dividends collected$8.61M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$253.00$256.15

Year-by-year: WLTW vs ABBV ($10,000, DRIP)

YearWLTW PortfolioWLTW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$13,261$2,560.64$11,550$430.00+$1.7KWLTW
2$18,546$4,357.13$13,472$627.96+$5.1KWLTW
3$27,664$7,819.39$15,906$926.08+$11.8KWLTW
4$44,567$14,966.43$19,071$1,382.55+$25.5KWLTW
5$78,625$30,938.86$23,302$2,095.81+$55.3KWLTW
6$154,168$70,039.55$29,150$3,237.93+$125.0KWLTW
7$341,184$176,223.76$37,536$5,121.41+$303.6KWLTW
8$865,498$500,431.41$50,079$8,338.38+$815.4KWLTW
9$2,555,038$1,628,954.60$69,753$14,065.80+$2.49MWLTW
10$8,904,483$6,170,593.00$102,337$24,771.77+$8.80MWLTW

WLTW vs ABBV: Complete Analysis 2026

WLTWStock

Willis Towers Watson Public Limited Company operates as an advisory, broking, and solutions company worldwide. The company's Human Capital and Benefits segment offers actuarial support, plan design, and administrative services for traditional pension and retirement savings plans; plan management consulting, broking, and administration services for health and group benefit programs; and benefits outsourcing services. It also provides advice, data, software, and products to address clients' total rewards and talent issues. Its Corporate Risk and Broking segment offers risk advice, insurance brokerage, and consulting services in the areas of property and casualty, aerospace, construction, and marine. The company's Investment, Risk and Reinsurance segment offers investment consulting and discretionary management services to insurance and reinsurance companies; insurance consulting and technology, risk and capital management, pricing and predictive modeling, financial and regulatory reporting, financial and capital modeling, merger and acquisition, outsourcing, and business management services; wholesale insurance broking services to retail and wholesale brokers; and underwriting and capital management, capital market, and advisory and brokerage services. Its Benefits Delivery and Administration segment provides primary medical and ancillary benefit exchange, and outsourcing services to active employees and retirees in the group and individual markets. This segment delivers healthcare and reimbursement accounts, including health savings accounts, health reimbursement arrangements, flexible spending accounts, and other consumer-directed accounts. The company was formerly known as Willis Group Holdings Public Limited Company and changed its name to Willis Towers Watson Public Limited Company in January 2016. Willis Towers Watson Public Limited Company was founded in 1828 and is based in London, the United Kingdom.

Full WLTW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WLTW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WLTW vs SCHDWLTW vs JEPIWLTW vs OWLTW vs KOWLTW vs MAINWLTW vs JNJWLTW vs MRKWLTW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.